Contact Us
Home Select Scientific Publications

Select Scientific Publications

Investor Contacts

investorinfo@jazzpharma.com
Ireland: +353 1 634 3211
U.S.: +1 650 496 2717 

Select Scientific Publications

This site is intended for a U.S. audience and includes information about investigational products, or investigational indications for FDA-approved products. Safety and efficacy have not been established, and there is no guarantee that pipeline products or investigational uses will receive FDA approval.

Gastroesophageal Adenocarcinoma (GEA)
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Publication: The Lancet Oncology 
Author: Elimova, E., et al
Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial
Publication: Journal of Clinical Oncology 
Author: Elimova, E., et al
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA)
Publication: Journal of Clinical Oncology
Author: Elimova, E., et al
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Publication: Future Oncology
Author: Tabernero, J., et al
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study
Publication: Journal of Clinical Oncology
Author: Meric-Bernstam, F., et al
Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Publication: ESMO Annals of Oncology
Author: Lee, K-W., et al
Other
Zanidatamab (Zani) + chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic colorectal cancer (mCRC)
Publication: Annals of Oncologyy
Author: Rha, S. Y., et al
Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study
Publication: Clinical Cancer Research
Author: Montero, A., et al
EmpowHER 303: A phase 3 study to evaluate the efficacy and safety of zanidatamab vs trastuzumab with chemotherapy in patients (pts) with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan
Publication: Clinical Cancer Research 
Author: Tolaney, S. M., et al
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Publication: The Lancet Oncology
Author: Meric-Bernstam, F., et al
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study
Publication: Journal of Clinical Oncology
Author: Wang, X., et al
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Publication: Nature Communications
Author: Weisser, N., et al
Super-resolution imaging studies of zanidatamab: Providing insights into its bispecific mode of action
Publication: Cancer Research
Author: Dixit, S., Abraham, L., et al
Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)
Publication: Cancer Research
Author: Escriva-de-Romani, S., et al
Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer
Publication: Cancer Research
Author: Velaro, V., et al
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer
Publication: Cancer Chemotherapy and Pharmacology
Author: Proctor, J., et al
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Publication: Cancer Research
Author: Shpektor, D., et all
720TiP Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
Publication: Annals of Oncology
Author: Naqash, A-R., et al
JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models
Publication: Cancer Research
Author: Hauptschein, R., et al
Rational combination platform trial design for children and young adults with Diffuse Midline Glioma: a report from PNOC 
Publication: Society for NeuroOncology
Author: Mueller, S., et al
A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma 
Publication: Society for NeuroOncology
Author: Jackson, E. R., et al
H3 K27M-altered Glioma and Diffuse Intrinsic Pontine Glioma: Semi-systematic Review of Treatment Landscape and Future Directions 
Publication: Society for NeuroOncology
Author: van den Bent, M., et al
H3K27M mutant glioma: Disease definition and biological underpinnings 
Publication: Neuro-Oncology
Author: Saratsis, A. M., et al
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma
Publication: Neuro-Oncol
Author: Arrillaga-Romany, I., et al
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia
Publication: Leukemia
Author: Nii, T., et al
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/ BIP
Publication: Oncotarget
Author: A Lev, A., et al
IND-Enabling Characterization Of Dual DRD2- And ClpP-Targeting Agent ONC206 As The Next Imipridone For Clinical Neuro-Oncology
Publication: Neuro-Oncol
Author: Prabhu, V., et al
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study
Publication: The Lancet
Author: Yves Dauvilliers
Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia
Publication: Nature and Science of Sleep
Author: Michael J Thorpy
Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia
Publication: Journal of Clinical Sleep Medicine
Author: Anne Marie Morse
Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idopathic Hypersomnia
Publication: Nature of Science of Sleep
Author: Michael J Thorpy
Symptom Severity and Treatment Satisfaction in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE) 
Publication: Nature of Science of Sleep
Author: Logan Douglas Schneider
Impairment in Functioning and Quality of Life in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE) 
Publication: Nature of Science of Sleep
Author: Joanne Stevens
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
Publication: Sleep
Author: Richard K Bogan
Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy
Publication: CNS Drugs
Author: Richard K Bogan
Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study
Publication: Sleep Medicine
Author: Charles J Bae
Dosing and transition characteristics in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study
Publication: Sleep Medicine
Author: Aatif M Husain
Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
Publication: Nature and Science of Sleep
Author: Logan D Schneider
Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy
Publication: Hypertension
Author: William B White
JZP-258 Dose Titration and Transition from Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With Cataplexy
Publication: Sleep
Author: Foldvary-Schaefer, N., et al
Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study
Publication: Sleep Medicine
Author: Bae, C., J., et al
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
Publication: CNS Drugs
Author: Dauvilliers, Y., et al
Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study
Publication: Sleep
Author: Ben-Joseph, R. H., et al
Cardiovascular Risks in People With Narcolepsy: Expert Panel Consensus Recommendations
Publication: Journal of the American Heart Association
Author: Kwon, Y., et al
Cardiovascular burden of narcolepsy: what have we learned and what do we still need to know?
Publication: Sleep
Author: Barateau, L., Dauvilleiers, Y., et al
Individualized Treatment Patterns for Patients with Narcolepsy Treated with Oxybate: A Clinical Practice Perspective
Publication: Nature and Science of Sleep
Author: Roy, A., et al
Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies
Publication: Clinical and Translational Science
Author: Chen, C., Jenkins, J., et al
Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy
Publication: Journal of Clinical Sleep Medicine
Author: Dauvilliers, Y., et al
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study
Publication: The Lancet Neurology
Author: Dauvilliers, Y., et al
Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia
Publication: Nature and Science of Sleep
Author: Thorpy, M. J., et al
Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia
Publication: Journal of Clinical Sleep Medicine
Author: Morse, A. M., et al
Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Epworth Sleepiness Scale Score
Publication: Sleep
Author: Rosenberg, R., et al
Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
Publication: Nature and Science of Sleep
Author: Schneider, L. D., et al
Impairment in Functioning and Quality of Life in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)
Publication: Nature and Science of Sleep
Author: Stevens, J., et al
Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients With Narcolepsy: A Commentary
Publication: Neurology and Therapy
Author: Rosenberg, R., et al
Low-Sodium Oxybate Improved Symptoms in Adults With Idiopathic Hypersomnia: A Plain Language Summary of Publication
Publication: Future Neurology
Author: Dauvilliers, Y., et al
Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations
Publication: Neurology and Therapy
Author: Morse, A., et al
Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM) 
Publication: Sleep Medicine
Author: Saad, R., et al
Experiences of people with narcolepsy who switched from sodium oxybate to low-sodium oxybate: a plain language summary 
Publication: Future Neurology
Author: Husain, A. M., et al
Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study
Publication: CNS Drugs
Author: David T. Plante
A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
Publication: Clinical Pharmacology in Drug Development
Author: Gilmour Morrison
A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
Publication: Epilepsia
Author: Julie Crockett
Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial
Publication: Epilepsy & Behavior
Author: Kerri A Schoedel
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Publication: CNS Drugs
Author: Lesley Taylor
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Publication: Neurology
Author: Orrin Devinsky
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy
Publication: CNS Drugs
Author: Elinor Ben-Menachem
A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam
Publication: Journal of Clinical Pharmacology
Author: Kevan E VanLandingham
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Publication: The New England Journal of Medicine
Author: Orrin Devinsky
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Publication: The Lancet
Author: Elizabeth A Thiele
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
Publication: JAMA Neurology
Author: Elizabeth A Thiele
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
Publication: JAMA Neurology
Author: Ian Miller
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
Publication: Epilepsia
Author: Jennifer Madan Cohen
Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials
Publication: Epilepsia
Author: Michael Privitera
The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome
Publication: Epilepsy & Behavior
Author: Stéphane Auvin
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results
Publication: Epilepsy & Research
Author: Linda C Laux
A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
Publication: Journal of Clinical Pharmacology
Author: Lesley Taylor
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
Publication: Clinical Pharmacokinetics
Author: Bola Tayo
A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects
Publication: Clinical Pharmacology in Drug Development
Author: Ching Thai
Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
Publication: Epilepsia
Author: Philip N Patsalos
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials
Publication: Acta Neurologica Scandinavica
Author: Orrin Devinsky
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
Publication: Acta Neurologica Scandinavica
Author: Boudewijn Gunning
Economic burden associated with tuberous sclerosis complex in patients with epilepsy
Publication: Epilepsy & Behavior
Author: Keith A Betts
Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome
Publication: Clinical Therapeutics
Author: Siu Hing Lo
Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex
Publication: PharmacoEconomics
Author: Siu Hing Lo
Impact of developmental and epileptic encephalopathies on caregivers: A literature review
Publication: Epilepsy & Behavior
Author: Katy Gallop
Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study
Publication: Epilepsy & Behavior
Author: Nancy L Reaven
The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis
Publication: Epilepsy & Behavior
Author: Nancy L Reaven
Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
Publication: Epilepsia
Author: Robert T Wechsler
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Publication: The New England Journal of Medicine
Author: Orrin Devinsky
Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies treated in the Expanded Access Program
Publication: Epilepsia
Author: Anup D Patel
Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)
Publication: PloS One
Author: Agnies M van Eeghen
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Publication: The New England Journal of Medicine
Author: Devinsky, O., et al
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
Publication: JAMA Neurology
Author: Thiele, E., et al
Seizure-free days as a novel outcome in patients with Lennox–Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials
Publication: Epilepsia
Author: Auvin, S., et al
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Publication: The New England Journal of Medicine
Author: Devinsky, O., et al
Long-term Safety and Efficacy of Add-on Cannabidiol in Patients with Lennox-Gastaut Syndrome: Results of a Long-Term Open Label Extension Trial
Publication: Epilepsia
Author: Patel, A., et al
Consensus panel recommendations for the optimization of EPIDIOLEX treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
Publication: Epilepsia Open
Author: Wechsler, R., et al
Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam
Publication: Experimental Neurology
Author: Rena, R., et al
Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome
Publication: Seizure: European Journal of Epilepsy
Author: Nabbout, R., et al
Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program
Publication: Epilepsia
Author: Szaflarski, J., et al
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program
Publication: Epilepsia
Author: Flamini, R. J., et al
Caregiver-Reported Seizure Outcomes with Real-World Use of Cannabidiol (CBD) in Tuberous Sclerosis Complex (TSC): Interim Results from the BECOME-TSC Survey
Publication: AES
Author: Koenig, M.K., et al
Nonseizure- and seizure-related benefits of cannabidiol treatment in the real world: plain language summary of the results from a caregiver survey
Publication: Future Neurology
Author: Berg, A.T., et al
Caregiver-Reported Nonseizure Outcomes With Real-World Use of Cannabidiol in Tuberous Sclerosis Complex: Interim Results From the BECOME-TSC Survey
Publication: AES
Author: Wilson, S., et al
Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity
Publication: Neuron
Author: Rosenberg, E., et al
Long-term Effectiveness of Cannabidiol (CBD) Against Focal-Onset Seizures in Treatment-Resistant Epilepsies (TRE)
Publication: AES
Author: Park, Y. D., et al
Real-World Outcomes of Cannabidiol (CBD) in Treatment-Resistant Focal Epilepsies: Experience from the Expanded Access Program (EAP)
Publication: American Epilepsy Society
Author: Patel, A., et al
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes
Publication: Epilepsy & Behavior
Author: Devinsky, O., et al
Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials
Publication: CNS Drugs
Author: Specchio, N., et al
Burden of illness in tuberous sclerosis complex-associated epilepsy: a systematic literature review of epidemiology, health-related quality of life, costs and resource use
Publication: Orphanet Journal of Rare Diseases
Author: Furber, A., et al
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
Publication: Blood
Author: Maese, L., et al
A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases
Publication: Journal of Clinical Oncology
Author: Maese, L., et al
Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia
Publication: Clinical and Translational Science
Author: Lin, T., et al
Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations
Publication: American Journal of Hematology
Author: Aldoss, I., et al
Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study
Publication: Journal of Thoracic Oncology
Author: Halmos, B., et al
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Publication: The Lancet
Author: Paz-Ares, L., et al
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial
Publication: Journal of Clinical Oncology
Author: Paz-Ares, L., et al
Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study
Publication: Journal of Clinical Oncology
Author: Ponce-Aix, S., et al
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Publication: The Lancet Oncology
Author: Trigo, J., et al
Efficacy of lurbinectedin in a clinical trial versus other standard of care in a real-world comparator arm in relapsed/refractory small cell lung cancer patients
Publication: Journal of Clinical Oncology
Author: Ganti, A., et al
Lurbinectedin in small cell lung cancer
Publication: Frontiers in Oncology
Author: Manzo, A., et al
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
Publication: The Lancet Respiratory Medicine
Author: Aix, S., et al
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
Publication: Annals of Oncology
Author: Calvo, E., et al
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
Publication: Invetigational New Drugs
Author: Olmedo, M., et al
Biliary Tract Cancers (BTC)
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZONBTC-01): a multicentre, single-arm, phase 2b study
Publication: The Lancet Oncology 
Author: Harding, J., Fa, J., Oh, D-Y., et al
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study 
Publication: 2024 ASCO Annual Meeting 
Author: Pant, S., et al
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
Publication: Future Oncology 
Author: Harding, J., et al
Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Publication: ESMO Annals of Oncology 
Author: Wasan, H.S., et al
HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
Publication: Journal of Clinical Oncology 
Author: Harding, J. J., et al
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer; Final Results From HERIZON-BTC-01 
Publication: JAMA Oncology
Author: Harding, J. J., et al
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma 
Publication: Journal of Clinical Oncology
Author: Arrillaga-Romany, I., et al
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Publication: Cancer Discovery
Author: Venneti, S., et al
Clinical Efficacy Of ONC201 In Recurrent H3 K27M-Mutant Diffuse Midline Glioma Patients
Publication: Society for NeuroOncology
Author: Arrillaga-Romany, I., et al